We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Laura
Coates
laura.coates@ndorms.ox.ac.uk
Mrs
Marian
Montgomery
marian.montgomery@ndorms.ox.ac.uk
Amy
Lawrence
Amy.Dawson@ndorms.ox.ac.uk
Diseases of liverInflammatory polyarthropathiesPapulosquamous disorders
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Patients with psoriatic disease have a much higher risk of developing non-alcoholic liver disease. This causes significant impact on their life and is a difficult clinical problem as some therapies for psoriasis and arthritis may worsen the liver disease. Previously the only tests available have been blood tests (which are often normal until the liver is quite damaged) or a liver biopsy (an invasive and risky procedure which only takes a very small sample of the liver). Our colleagues have developed and tested a new type of MRI scan which can measure inflammation and scarring in the liver allowing us to study liver disease in detail.
We want to use this new technology to study the proportion of people with psoriasis who may also have associated liver disease and measure how severe this is. We will use blood, urine and stool samples to study why and how the liver disease develops in many people with psoriatic disease. We will repeat the scans and research samples after 6 months on a new treatment to see how common psoriasis treatments affect both inflammation and scarring in liver disease.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Validation of investigation /therapeutic procedures;
You can take part if:
You may not be able to take part if:
The participant may not enter the study if ANY of the following apply: • The participant may not enter the study if they have any contraindication to magnetic resonance imaging (including pregnancy, extensive tattoos, pacemaker, shrapnel injury, severe claustrophobia). • Patients with autoimmune hepatitis, viral hepatitis and Wilson’s disease. • Any other cause, including a significant disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or may influence the participant’s ability to participate in the study
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Mrs
Marian
Montgomery
marian.montgomery@ndorms.ox.ac.uk
Amy
Lawrence
Amy.Dawson@ndorms.ox.ac.uk
Dr
Laura
Coates
laura.coates@ndorms.ox.ac.uk
The study is sponsored by University of Oxford and funded by NATIONAL PSORIASIS FOUNDATION (USA) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 44926
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
